Limbic system pathologies associated with deficiencies and excesses of the trace elements iron, zinc, copper, and selenium

Nutrition Reviews

Volumn 70, Issue 12, 2012, Pages 679-692

  Torres Vega, Adriana ^a   Pliego Rivero, Bernardo F ^a   Otero Ojeda, Gloria A ^a   Gómez Oliván, Leobardo M ^a   Vieyra Reyes, Patricia ^a  

^a UNIVERSIDAD AUTÓNOMA DEL ESTADO DE MÉXICO   (Mexico)

Author keywords

Copper; Iron; Limbic system; Selenium; Zinc

Indexed keywords

COPPER; IRON; SELENIUM; SELENOPROTEIN P; ZINC;

AMYGDALOID NUCLEUS; ATTENTION DEFICIT DISORDER; BRAIN FUNCTION; CINGULATE GYRUS; COPPER DEFICIENCY; COPPER EXCESS; COPPER METABOLISM; CORPUS STRIATUM; DEPRESSION; DIABETES MELLITUS; EMOTION; EPILEPSY; EVOKED RESPONSE; FRIEDREICH ATAXIA; HUMAN; HUNTINGTON CHOREA; HYPOTHALAMUS; IRON ABSORPTION; IRON BINDING CAPACITY; IRON DEFICIENCY; IRON EXCESS; IRON METABOLISM; IRON TRANSPORT; LEWY BODY; LIMBIC SYSTEM; MENKES SYNDROME; MYELINATION; NEUROCHEMISTRY; NEUROLOGIC DISEASE; NEUROTRANSMISSION; NUCLEUS ACCUMBENS; NUTRITIONAL DISORDER; OLIGODENDROGLIA; ORBITAL CORTEX; OXIDATIVE STRESS; PARAHIPPOCAMPAL GYRUS; PARKINSON DISEASE; PREFRONTAL CORTEX; PREGNANCY; PROTEIN EXPRESSION; REVIEW; REWARD; SCHIZOPHRENIA; SELENIUM DEFICIENCY; SUBSTANTIA NIGRA; WILSON DISEASE; ZINC DEFICIENCY; ZINC EXCESS; ZINC METABOLISM;

BRAIN DISEASES; COPPER; HUMANS; IRON; LIMBIC SYSTEM; NUTRITIONAL PHYSIOLOGICAL PHENOMENA; NUTRITIONAL REQUIREMENTS; SELENIUM; TRACE ELEMENTS; ZINC;

EID: 84870546255     PISSN: 00296643     EISSN: 17534887     Source Type: Journal    
DOI: 10.1111/j.1753-4887.2012.00521.x     Document Type: Review

References (142)

1. Gao S, Jin Y, Unverzagt FW, etal. Trace element levels and cognitive function in rural elderly Chinese. J Gerontol A Biol Sci Med Sci. 2008;63:635-641.
2. Rice D, Barone S Jr. Critical periods of vulnerability for the developing nervous system: evidence from humans and animal models. Environ Health Perspect. 2000;108(Suppl 3):511-533.
3. Burdette SC, Lippard SJ. Meeting of the minds: metalloneurochemistry. Proc Natl Acad Sci U S A. 2003;100:3605-3610.
4. Goldstein DS. Catecholamines 101. Clin Auton Res. 2010;20:331-352.
5. Blum K, Chen AL, Chen TJ, etal. Activation instead of blocking mesolimbic dopaminergic reward circuitry is a preferred modality in the long term treatment of reward deficiency syndrome (RDS): a commentary. Theor Biol Med Model. 2008;5:24.
6. Robinson DL, Zitzman DL, Williams SK. Mesolimbic dopamine transients in motivated behaviors: focus on maternal behavior. Front Psychiatry. 2011;2:23.
7. Korchounov A, Meyer MF, Krasnianski M. Postsynaptic nigrostriatal dopamine receptors and their role in movement regulation. J Neural Transm. 2010;117:1359-1369.
8. Robinson DL, Hermans A, Seipel AT, etal. Monitoring rapid chemical communication in the brain. Chem Rev. 2008;108:2554-2584.
9. Ventura R, Latagliata EC, Morrone C, etal. Prefrontal norepinephrine determines attribution of "high" motivational salience. PLoS ONE. 2008;3:e3044.
10. Latagliata EC, Patrono E, Puglisi-Allegra S, etal. Food seeking in spite of harmful consequences is under prefrontal cortical noradrenergic control. BMC Neurosci. 2010;11:15.
11. Tully K, Bolshakov VY. Emotional enhancement of memory: how norepinephrine enables synaptic plasticity. Mol Brain. 2010;3:15.
12. Sanders JD, Happe HK, Bylund DB, etal. Differential effects of neonatal norepinephrine lesions on immediate early gene expression in developing and adult rat brain. Neuroscience. 2008;157:821-832.
13. Aguirre P, Mena N, Tapia V, etal. Iron homeostasis in neuronal cells: a role for IREG1. BMC Neurosci. 2005;6:3.
14. Dexter DT, Carayon A, Javoy-Agid F, etal. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia. Brain. 1991;114(Pt 4):1953-1975.
15. Thomas B, von Coelln R, Mandir AS, etal. MPTP and DSP-4 susceptibility of substantia nigra and locus coeruleus catecholaminergic neurons in mice is independent of parkin activity. Neurobiol Dis. 2007;26:312-322.
16. Gutteridge JM. Iron and oxygen radicals in brain. Ann Neurol. 1992;32(Suppl):S16-S21.
17. Herrera-Rivero M, Hernández-Aguilar ME, Manzo J, etal. Enfermedad de Alzheimer: inmunidad y diagnóstico [in Spanish]. Rev Neurol. 2010;51:153-164.
18. Koh JY. Endogenous zinc in neurological diseases. J Clin Neurol. 2005;1:121-133.
19. van Roon-Mom WM, Pepers BA, t Hoen PA, etal. Mutant huntingtin activates Nrf2-responsive genes and impairs dopamine synthesis in a PC12 model of Huntington's disease. BMC Mol Biol. 2008;9:84.
20. Ben-Shachar D, Eshel G, Finberg JP, etal. The iron chelator desferrioxamine (Desferal) retards 6-hydroxydopamine-induced degeneration of nigrostriatal dopamine neurons. J Neurochem. 1991;56:1441-1444.
21. Rosas HD, Salat DH, Lee SY, etal. Cerebral cortex and the clinical expression of Huntington's disease: complexity and heterogeneity. Brain. 2008;131(Pt 4):1057-1068.
22. Wong ML, Licinio J. Research and treatment approaches to depression. Nat Rev Neurosci. 2001;2:343-351.
23. Wright Willis A, Evanoff BA, Lian M, etal. Geographic and ethnic variation in Parkinson disease: a population-based study of US Medicare beneficiaries. Neuroepidemiology. 2010;34:143-151.
24. Bekris LM, Yu CE, Bird TD, etal. Genetics of Alzheimer disease. J Geriatr Psychiatry Neurol. 2010;23:213-227.
25. White T, Cullen K, Rohrer LM, etal. Limbic structures and networks in children and adolescents with schizophrenia. Schizophr Bull. 2008;34:18-29.
26. Rajmohan V, Mohandas E. The limbic system. Indian J Psychiatry. 2007;49:132-139.
27. Yakovlev PI. Motility, behavior and the brain; stereodynamic organization and neural coordinates of behavior. J Nerv Ment Dis. 1948;107:313-335.
28. Maclean PD, Flanigan S, Flynn JP, etal. Hippocampal function: tentative correlations of conditioning, EEG, drug, and radioautographic studies. Yale J Biol Med. Dec 1956 Feb 1955;28:380-395.
29. Laviolette SR. Dopamine modulation of emotional processing in cortical and subcortical neural circuits: evidence for a final common pathway in schizophrenia? Schizophr Bull. 2007;33:971-981.
30. Ferris CF, Stolberg T, Kulkarni P, etal. Imaging the neural circuitry and chemical control of aggressive motivation. BMC Neurosci. 2008;9:111.
31. Guillemin R, Perrin MH. Neuroendocrinology: past, present and future. Ann Endocrinol (Paris). 2008;69:160.
32. Haas BW, Canli T. Emotional memory function, personality structure and psychopathology: a neural system approach to the identification of vulnerability markers. Brain Res Rev. 2008;58:71-84.
33. Kober H, Barrett LF, Joseph J, etal. Functional grouping and cortical-subcortical interactions in emotion: a meta-analysis of neuroimaging studies. Neuroimage. 2008;42:998-1031.
34. Lin B, Levy S, Raval AP, etal. Forebrain ischemia triggers GABAergic system degeneration in substantia nigra at chronic stages in rats. Cardiovasc Psychiatry Neurol. 2010;2010:506952.
35. Marsden CA. Dopamine: the rewarding years. Br J Pharmacol. 2006;147(Suppl 1):S136-S144.
36. Alcaro A, Huber R, Panksepp J. Behavioral functions of the mesolimbic dopaminergic system: an affective neuroethological perspective. Brain Res Rev. 2007;56:283-321.
37. West AR, Oates PS. Mechanisms of heme iron absorption: current questions and controversies. World J Gastroenterol. 2008;14:4101-4110.
38. 2 reduction site of fully oxidized cytochrome c oxidase could suppress the proton pump. Proc Natl Acad Sci U S A. 2009;106:2165-2169.
39. Moos T, Rosengren Nielsen T, Skjorringe T, etal. Iron trafficking inside the brain. J Neurochem. 2007;103:1730-1740.
40. Ortega R, Cloetens P, Deves G, etal. Iron storage within dopamine neurovesicles revealed by chemical nano-imaging. PLoS ONE. 2007;2:e925.
41. López-García C, Molowny A, Ponsoda X, etal. [Synaptic zinc in the central nervous system][in Spanish]. Rev Neurol. 2001;33:341-347.
42. Genereux JC, Boal AK, Barton JK. DNA-mediated charge transport in redox sensing and signaling. J Am Chem Soc. 2010;132:891-905.
43. Walsh CT, Sandstead HH, Prasad AS, etal. Zinc: health effects and research priorities for the 1990s. Environ Health Perspect. 1994;102(Suppl 2):5-46.
44. Watt NT, Whitehouse IJ, Hooper NM. The role of zinc in Alzheimer's disease. Int J Alzheimers Dis. 2010;2011:971021.
45. Takeda A, Sakurada N, Ando M, etal. Facilitation of zinc influx via AMPA/kainate receptor activation in the hippocampus. Neurochem Int. 2009;55:376-382.
46. Cote A, Chiasson M, Peralta MR III, etal. Cell type-specific action of seizure-induced intracellular zinc accumulation in the rat hippocampus. J Physiol. 2005;566(Pt 3):821-837.
47. Prohaska JR. Role of copper transporters in copper homeostasis. Am J Clin Nutr. 2008;88:S826-S829.
48. Horn D, Barrientos A. Mitochondrial copper metabolism and delivery to cytochrome c oxidase. IUBMB Life. 2008;60:421-429.
49. Gupta A, Lutsenko S. Human copper transporters: mechanism, role in human diseases and therapeutic potential. Future Med Chem. 2009;1:1125-1142.
50. Kumar N. Copper deficiency myelopathy (human swayback). Mayo Clin Proc. 2006;81:1371-1384.
51. La Fontaine S, Mercer JF. Trafficking of the copper-ATPases, ATP7A and ATP7B: role in copper homeostasis. Arch Biochem Biophys. 2007;463:149-167.
52. Bousquet-Moore D, Prohaska JR, Nillni EA, etal. Interactions of peptide amidation and copper: novel biomarkers and mechanisms of neural dysfunction. Neurobiol Dis. 2010;37:130-140.
53. Setty SR, Tenza D, Sviderskaya EV, etal. Cell-specific ATP7A transport sustains copper-dependent tyrosinase activity in melanosomes. Nature. 2008;454:1142-1146.
54. Prohaska JR, Broderius M. Plasma peptidylglycine alpha-amidating monooxygenase (PAM) and ceruloplasmin are affected by age and copper status in rats and mice. Comp Biochem Physiol B Biochem Mol Biol. 2006;143:360-366.
55. Barnes KM, Evenson JK, Raines AM, etal. Transcript analysis of the selenoproteome indicates that dietary selenium requirements of rats based on selenium-regulated selenoprotein mRNA levels are uniformly less than those based on glutathione peroxidase activity. J Nutr. 2009;139:199-206.
56. Lu J, Zhong L, Lonn ME, etal. Penultimate selenocysteine residue replaced by cysteine in thioredoxin reductase from selenium-deficient rat liver. FASEB J. 2009;23:2394-2402.
57. St Germain DL, Galton VA, Hernandez A. Minireview: defining the roles of the iodothyronine deiodinases: current concepts and challenges. Endocrinology. 2009;150:1097-1107.
58. Lobanov AV, Hatfield DL, Gladyshev VN. Reduced reliance on the trace element selenium during evolution of mammals. Genome Biol. 2008;9:R62.
59. Nakayama A, Hill KE, Austin LM, etal. All regions of mouse brain are dependent on selenoprotein P for maintenance of selenium. J Nutr. 2007;137:690-693.
60. Mills E, Dong XP, Wang F, etal. Mechanisms of brain iron transport: insight into neurodegeneration and CNS disorders. Future Med Chem. 2010;2:51-64.
61. Rouault TA, Zhang DL, Jeong SY. Brain iron homeostasis, the choroid plexus, and localization of iron transport proteins. Metab Brain Dis. 2009;24:673-684.
62. Beard J. Iron deficiency alters brain development and functioning. J Nutr. 2003;133(5 Suppl 1):S1468-S1472.
63. Youdim MB. Brain iron deficiency and excess; cognitive impairment and neurodegeneration with involvement of striatum and hippocampus. Neurotox Res. 2008;14:45-56.
64. Ono S, Cherian MG. Regional distribution of metallothionein, zinc, and copper in the brain of different strains of rats. Biol Trace Elem Res. 1999;69:151-159.
65. Karol N, Brodski C, Bibi Y, etal. Zinc homeostatic proteins in the CNS are regulated by crosstalk between extracellular and intracellular zinc. J Cell Physiol. 2010;224:567-574.
66. Xie X, Smart TG. Properties of GABA-mediated synaptic potentials induced by zinc in adult rat hippocampal pyramidal neurones. J Physiol. 1993;460:503-523.
67. Long Y, Hardwick AL, Frederickson CJ. Zinc-containing innervation of the subicular region in the rat. Neurochem Int. 1995;27:95-103.
68. Kauppinen TM, Higashi Y, Suh SW, etal. Zinc triggers microglial activation. J Neurosci. 2008;28:5827-5835.
69. Kay AR, Tóth K. Is zinc a neuromodulator? Sci Signal. 2008;1:re3.
70. Colvin RA, Davis N, Nipper RW, etal. Zinc transport in the brain: routes of zinc influx and efflux in neurons. J Nutr. 2000;130(5S Suppl):S1484-S1487.
71. Frederickson CJ, Suh SW, Silva D, etal. Importance of zinc in the central nervous system: the zinc-containing neuron. J Nutr. 2000;130(5S Suppl):S1471-S1483.
72. Elsas SM, Hazany S, Gregory WL, etal. Hippocampal zinc infusion delays the development of afterdischarges and seizures in a kindling model of epilepsy. Epilepsia. 2009;50:870-879.
73. Moreno CB, Gutiérrez-Alvarez AM, González-Reyes RE. [Zinc and epilepsy: is there a causal relation between them?][in Spanish]. Rev Neurol. 2006;42:754-759.
74. Boal AK, Rosenzweig AC. Structural biology of copper trafficking. Chem Rev. 2009;109:4760-4779.
75. Kuo YM, Gybina AA, Pyatskowit JW, etal. Copper transport protein (Ctr1) levels in mice are tissue specific and dependent on copper status. J Nutr. 2006;136:21-26.
76. Yang H, Brosel S, Acin-Perez R, etal. Analysis of mouse models of cytochrome c oxidase deficiency owing to mutations in Sco2. Hum Mol Genet. 2010;19:170-180.
77. Burk RF, Hill KE, Read R, etal. Response of rat selenoprotein P to selenium administration and fate of its selenium. Am J Physiol. 1991;261(1 Pt 1):E26-E30.
78. Burk RF, Hill KE, Olson GE, etal. Deletion of apolipoprotein E receptor-2 in mice lowers brain selenium and causes severe neurological dysfunction and death when a low-selenium diet is fed. J Neurosci. 2007;27:6207-6211.
79. Peters MM, Hill KE, Burk RF, etal. Altered hippocampus synaptic function in selenoprotein P deficient mice. Mol Neurodegener. 2006;1:12.
80. Masiulis I, Quill TA, Burk RF, etal. Differential functions of the Apoer2 intracellular domain in selenium uptake and cell signaling. Biol Chem. 2009;390:67-73.
81. Richardson DR. More roles for selenoprotein P: local selenium storage and recycling protein in the brain. Biochem J. 2005;386(Pt 2):e5-e7.
82. Schweizer U, Streckfuss F, Pelt P, etal. Hepatically derived selenoprotein P is a key factor for kidney but not for brain selenium supply. Biochem J. 2005;386(Pt 2):221-226.
83. Siddappa AM, Rao R, Long JD, etal. The assessment of newborn iron stores at birth: a review of the literature and standards for ferritin concentrations. Neonatology. 2007;92:73-82.
84. Georgieff MK. The role of iron in neurodevelopment: fetal iron deficiency and the developing hippocampus. Biochem Soc Trans. 2008;36(Pt 6):1267-1271.
85. Schmidt AT, Waldow KJ, Grove WM, etal. Dissociating the long-term effects of fetal/neonatal iron deficiency on three types of learning in the rat. Behav Neurosci. 2007;121:475-482.
86. Burden MJ, Westerlund AJ, Armony-Sivan R, etal. An event-related potential study of attention and recognition memory in infants with iron-deficiency anemia. Pediatrics. 2007;120:336-345.
87. de Deungria M, Rao R, Wobken JD, etal. Perinatal iron deficiency decreases cytochrome c oxidase (CytOx) activity in selected regions of neonatal rat brain. Pediatr Res. 2000;48:169-176.
88. Siddappa AM, Georgieff MK, Wewerka S, etal. Iron deficiency alters auditory recognition memory in newborn infants of diabetic mothers. Pediatr Res. 2004;55:1034-1041.
89. Lozoff B, Jimenez E, Smith JB. Double burden of iron deficiency in infancy and low socioeconomic status: a longitudinal analysis of cognitive test scores to age 19 years. Arch Pediatr Adolesc Med. 2006;160:1108-1113.
90. McCann JC, Ames BN. An overview of evidence for a causal relation between iron deficiency during development and deficits in cognitive or behavioral function. Am J Clin Nutr. 2007;85:931-945.
91. Rao R, Tkac I, Townsend EL, etal. Perinatal iron deficiency predisposes the developing rat hippocampus to greater injury from mild to moderate hypoxia-ischemia. J Cereb Blood Flow Metab. 2007;27:729-740.
92. Shao J, Xi G, Hua Y, etal. Intracerebral hemorrhage in the iron-deficient rat. Stroke. 2005;36:660-664.
93. Ortiz E, Pasquini JM, Thompson K, etal. Effect of manipulation of iron storage, transport, or availability on myelin composition and brain iron content in three different animal models. J Neurosci Res. 2004;77:681-689.
94. Beard JL. Why iron deficiency is important in infant development. J Nutr. 2008;138:2534-2536.
95. Wu LL, Zhang L, Shao J, etal. Effect of perinatal iron deficiency on myelination and associated behaviors in rat pups. Behav Brain Res. 2008;188:263-270.
96. Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008;455:894-902.
97. Corapci F, Radan AE, Lozoff B. Iron deficiency in infancy and mother-child interaction at 5 years. J Dev Behav Pediatr. 2006;27:371-378.
98. Sørensen HJ, Nielsen PR, Pedersen CB, etal. Association between prepartum maternal iron deficiency and offspring risk of schizophrenia: population-based cohort study with linkage of Danish national registers. Schizophr Bull. 2011;37:982-987.
99. Curatolo P, D'Agati E, Moavero R. The neurobiological basis of ADHD. Ital J Pediatr. 2010;36:79.
100. Konofal E, Cortese S. Lead and neuroprotection by iron in ADHD. Environ Health Perspect. 2007;115:A398-A399; author reply A399.
101. Plessen KJ, Bansal R, Zhu H, etal. Hippocampus and amygdala morphology in attention-deficit/hyperactivity disorder. Arch Gen Psychiatry. 2006;63:795-807.
102. Romanos M, Weise D, Schliesser M, etal. Structural abnormality of the substantia nigra in children with attention-deficit hyperactivity disorder. J Psychiatry Neurosci. 2010;35:55-58.
103. Jomova K, Vondrakova D, Lawson M, etal. Metals, oxidative stress and neurodegenerative disorders. Mol Cell Biochem. 2010;345:91-104.
104. Stankiewicz J, Panter SS, Neema M, etal. Iron in chronic brain disorders: imaging and neurotherapeutic implications. Neurotherapeutics. 2007;4:371-386.
105. Gaeta A, Hider RC. The crucial role of metal ions in neurodegeneration: the basis for a promising therapeutic strategy. Br J Pharmacol. 2005;146:1041-1059.
106. Mastroberardino PG, Hoffman EK, Horowitz MP, etal. A novel transferrin/TfR2-mediated mitochondrial iron transport system is disrupted in Parkinson's disease. Neurobiol Dis. 2009;34:417-431.
107. Hayflick SJ, Hartman M, Coryell J, etal. Brain MRI in neurodegeneration with brain iron accumulation with and without PANK2 mutations. AJNR Am J Neuroradiol. 2006;27:1230-1233.
108. Shepherd M. Report of a family suffering from Friedreich's disease, peroneal muscular atrophy, and schizophrenia. J Neurol Neurosurg Psychiatry. 1955;18:297-304.
109. Jesse S, Steinacker P, Lehnert S, etal. Neurochemical approaches in the laboratory diagnosis of Parkinson and Parkinson dementia syndromes: a review. CNS Neurosci Ther. 2009;15:157-182.
110. Zecca L, Zucca FA, Albertini A, etal. A proposed dual role of neuromelanin in the pathogenesis of Parkinson's disease. Neurology. 2006;67(7 Suppl 2):S8-S11.
111. Strozyk D, Launer LJ, Adlard PA, etal. Zinc and copper modulate Alzheimer Abeta levels in human cerebrospinal fluid. Neurobiol Aging. 2009;30:1069-1077.
112. Gao HL, Zheng W, Xin N, etal. Zinc deficiency reduces neurogenesis accompanied by neuronal apoptosis through caspase-dependent and -independent signaling pathways. Neurotox Res. 2009;16:416-425.
113. Golub MS, Takeuchi PT, Keen CL, etal. Modulation of behavioral performance of prepubertal monkeys by moderate dietary zinc deprivation. Am J Clin Nutr. 1994;60:238-243.
114. Takeda A, Takefuta S, Okada S, etal. Relationship between brain zinc and transient learning impairment of adult rats fed zinc-deficient diet. Brain Res. 2000;859:352-357.
115. Suh SW, Won SJ, Hamby AM, etal. Decreased brain zinc availability reduces hippocampal neurogenesis in mice and rats. J Cereb Blood Flow Metab. 2009;29:1579-1588.
116. Koh JY, Choi DW. Zinc toxicity on cultured cortical neurons: involvement of N-methyl-D-aspartate receptors. Neuroscience. 1994;60:1049-1057.
117. Choi DW, Yokoyama M, Koh J. Zinc neurotoxicity in cortical cell culture. Neuroscience. 1988;24:67-79.
118. 2+ entry produces oxidative neuronal necrosis in cortical cell cultures. Eur J Neurosci. 1999;11:327-334.
119. Noh KM, Kim YH, Koh JY. Mediation by membrane protein kinase C of zinc-induced oxidative neuronal injury in mouse cortical cultures. J Neurochem. 1999;72:1609-1616.
120. Buhl EH, Otis TS, Mody I. Zinc-induced collapse of augmented inhibition by GABA in a temporal lobe epilepsy model. Science. 1996;271:369-373.
121. Ritchie CW, Bush AI, Mackinnon A, etal. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol. 2003;60:1685-1691.
122. Lee JY, Kim JH, Palmiter RD, etal. Zinc released from metallothionein-iii may contribute to hippocampal CA1 and thalamic neuronal death following acute brain injury. Exp Neurol. 2003;184:337-347.
123. Cho IH, Hong J, Suh EC, etal. Role of microglial IKKbeta in kainic acid-induced hippocampal neuronal cell death. Brain. 2008;131(Pt 11):3019-3033.
124. Carson MJ, Thrash JC, Walter B. The cellular response in neuroinflammation: the role of leukocytes, microglia and astrocytes in neuronal death and survival. Clin Neurosci Res. 2006;6:237-245.
125. Klinman JP, Brenner M. Role of copper and catalytic mechanism in the copper monooxygenase, dopamine beta-hydroxylase (D beta H). Prog Clin Biol Res. 1988;274:227-248.
126. Gerbasi V, Lutsenko S, Lewis EJ. A mutation in the ATP7B copper transporter causes reduced dopamine beta-hydroxylase and norepinephrine in mouse adrenal. Neurochem Res. 2003;28:867-873.
127. Pyatskowit JW, Prohaska JR. Rodent brain and heart catecholamine levels are altered by different models of copper deficiency. Comp Biochem Physiol C Toxicol Pharmacol. 2007;145:275-281.
128. Goldstein DS, Holmes CS, Kaler SG. Relative efficiencies of plasma catechol levels and ratios for neonatal diagnosis of Menkes disease. Neurochem Res. 2009;34:1464-1468.
129. Hess C, Reif A, Strobel A, etal. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transm. 2009;116:121-130.
130. Robbins TW, Arnsten AF. The neuropsychopharmacology of fronto-executive function: monoaminergic modulation. Annu Rev Neurosci. 2009;32:267-287.
131. Banaschewski T, Becker K, Scherag S, etal. Molecular genetics of attention-deficit/hyperactivity disorder: an overview. Eur Child Adolesc Psychiatry. 2010;19:237-257.
132. Heneka MT, Nadrigny F, Regen T, etal. Locus ceruleus controls Alzheimer's disease pathology by modulating microglial functions through norepinephrine. Proc Natl Acad Sci U S A. 2010;107:6058-6063.
133. Schlief ML, Craig AM, Gitlin JD. NMDA receptor activation mediates copper homeostasis in hippocampal neurons. J Neurosci. 2005;25:239-246.
134. Wang H, Lim PJ, Karbowski M, etal. Effects of overexpression of huntingtin proteins on mitochondrial integrity. Hum Mol Genet. 2009;18:737-752.
135. Fox JH, Kama JA, Lieberman G, etal. Mechanisms of copper ion mediated Huntington's disease progression. PLoS ONE. 2007;2:e334.
136. Haug A, Graham RD, Christophersen OA, etal. How to use the world's scarce selenium resources efficiently to increase the selenium concentration in food. Microb Ecol Health Dis. 2007;19:209-228.
137. Zhang Y, Zhou Y, Schweizer U, etal. Comparative analysis of selenocysteine machinery and selenoproteome gene expression in mouse brain identifies neurons as key functional sites of selenium in mammals. J Biol Chem. 2008;283:2427-2438.
138. Hill KE, Zhou J, McMahan WJ, etal. Neurological dysfunction occurs in mice with targeted deletion of the selenoprotein P gene. J Nutr. 2004;134:157-161.
139. Burk RF, Hill KE, Motley AK, etal. Deletion of selenoprotein P upregulates urinary selenium excretion and depresses whole-body selenium content. Biochim Biophys Acta. 2006;1760:1789-1793.
140. Gao S, Jin Y, Hall KS, etal. Selenium level and cognitive function in rural elderly Chinese. Am J Epidemiol. 2007;165:955-965.
141. Yakovlev A, Khafizova M, Abdullaev Z, etal. Epigenetic regulation of caspase-3 gene expression in rat brain development. Gene. 2010;450:103-108.
142. Savaskan NE, Brauer AU, Kuhbacher M, etal. Selenium deficiency increases susceptibility to glutamate-induced excitotoxicity. FASEB J. 2003;17:112-114.